Stockscreener 앱 받기
49.98
2.14%
-1.095
시장 영업 전:
49.98
0.005
+0.01%
전일 마감가:
$51.07
열려 있는:
$51.23
하루 거래량:
1.61M
Relative Volume:
0.90
시가총액:
$7.90B
수익:
$1.17B
순이익/손실:
$150.71M
주가수익비율:
53.16
EPS:
0.94
순현금흐름:
$245.03M
1주 성능:
-7.57%
1개월 성능:
-19.60%
6개월 성능:
-30.40%
1년 성능:
-21.93%
1일 변동 폭
$49.72
$51.87
1주일 범위
$48.40
$53.00
52주 변동 폭
$46.44
$85.57
바이오-테크네 Stock (TECH) Company Profile
명칭
Bio Techne Corp
전화
(612) 379-8854
주소
614 MCKINLEY PL N E, MINNEAPOLIS, MN
TECH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
49.98 | 7.90B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오-테크네 Stock (TECH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-08 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-02 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-08-28 | 개시 | William Blair | Outperform |
| 2023-01-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | 업그레이드 | Stifel | Hold → Buy |
| 2021-01-25 | 재확인 | The Benchmark Company | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 개시 | Atlantic Equities | Overweight |
| 2020-07-15 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-14 | 개시 | The Benchmark Company | Buy |
| 2020-01-08 | 재개 | Stephens | Overweight |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-07-02 | 업그레이드 | Janney | Neutral → Buy |
| 2019-01-14 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-10-17 | 개시 | Goldman | Neutral |
| 2018-06-15 | 개시 | Argus | Buy |
| 2017-07-13 | 개시 | Wells Fargo | Market Perform |
| 2017-02-09 | 개시 | Citigroup | Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-01-21 | 재확인 | Robert W. Baird | Outperform |
| 2013-09-20 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
모두보기
바이오-테크네 주식(TECH)의 최신 뉴스
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu - MSN
Bio-Techne Sets Date for Q3 2025 Financial Results: Key Details for Investors - Stock Titan
Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? - Yahoo Finance
Bio-Techne (TECH) Faces Downgrade Amid NIH Funding Concerns - GuruFocus
Forecasting The Future: 6 Analyst Projections For Bio-Techne - Benzinga
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Bio-Techne stock downgraded at KeyBanc (TECH:NASDAQ) - Seeking Alpha
KeyBanc Downgrades Bio-Techne to Sector Weight From Overweight - MarketScreener
KeyBanc cuts Bio-Techne stock rating on funding concerns By Investing.com - Investing.com India
KeyBanc cuts Bio-Techne stock rating on funding concerns - Investing.com
Trading (TECH) With Integrated Risk Controls - news.stocktradersdaily.com
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Spatial Genomics and Transcriptomics Industry Analysis Report 2025, Featuring Detailed Profiles of Leading Players10x Genomics, Bruker Corp., Akoya Biosciences, and Bio-Techne Among OthersResearchAndMarkets.com - Bluefield Daily Telegraph
Techne Corp stock hits 52-week low at $56.58 amid market shifts - Investing.com
Bio-Techne Expands Collaboration With Leica To Enhance Spatial Multiomics Research Capabilities - Nasdaq
Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument - PR Newswire
Bio-Techne's New Automated Spatial Multiomics Platform Transforms Research Capabilities - Stock Titan
Is Bio-Techne Corporation Stock Underperforming the S&P 500? - Nasdaq
Is Bio-Techne Corporation Stock Underperforming The S&P 500? - Barchart.com
Exosomes Market Detailed In New Research Report 2025 | Thermo Fisher Scientific, Inc., Bio-Techne, QIAGEN, Lonza - openPR.com
Bio-Techne Opens New Customer Experience Centre in Germany - Nasdaq
3 Reasons to Avoid TECH and 1 Stock to Buy Instead - Yahoo Finance
Research Tools & Consumables Stocks Q4 Earnings: Bio-Techne (NASDAQ:TECH) Best of the Bunch - Yahoo Finance
Bio-Techne to Open New Customer Facility in Germany - Marketscreener.com
Bio-Techne's New Tech Hub Targets Major European Life Sciences Growth - Stock Titan
Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting - Quantisnow
Game-Changing Cancer Detection Technology: RNAscope Shows Superior Results in Multiple Tumors - Stock Titan
Bio-Techne Earnings Preview: What to Expect - MSN
Evercore ISI Group Initiates Coverage of Bio-Techne (TECH) with Outperform Recommendation - MSN
Evercore ISI sets Bio-Techne stock Outperform with $75 target By Investing.com - Investing.com South Africa
6 Analysts Assess Bio-Techne: What You Need To Know - Benzinga
Evercore ISI sets Bio-Techne stock Outperform with $75 target - Investing.com
Bio-Techne: A Premium Growth Asset with Strong Market Position and Promising Future - TipRanks
Bio-Techne (NASDAQ:TECH) shareholders have earned a 8.3% CAGR over the last five years - Yahoo Finance
Bio-Techne (NASDAQ:TECH) Downgraded by StockNews.com to "Hold" - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Receives $82.14 Consensus Price Target from Analysts - Defense World
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Bio Techne at Barclays Conference: Strategic Growth Amid Market Challenges - Investing.com
TECH Stock Might Rise Following the Leo Shipping Announcement - Nasdaq
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Bio-Techne at Leerink’s Global Healthcare Conference: Strategic Growth Amid Challenges - Investing.com India
Techne Corp stock hits 52-week low at $58.94 amid market shifts - Investing.com India
Techne Corp stock hits 52-week low at $58.94 amid market shifts By Investing.com - Investing.com South Africa
GC Wealth Management RIA LLC Takes $805,000 Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Corp (TECH) Q1 FY2025 Earnings: Revenue Surpasses Est - GuruFocus.com
Bio-Techne Begins Shipping LeoA Next Generation High-Throughput Simple Western System - Quantisnow
Bio-Techne launches high-throughput Leo System - Investing.com
Bio-Techne's New Leo System Revolutionizes Protein Analysis Speed - StockTitan
Bio-Techne Corp. to Host Earnings Call - ACCESS Newswire
(TECH) Trading Advice - Stock Traders Daily
Techne (TECH) Down 15.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
바이오-테크네 (TECH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오-테크네 주식 (TECH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Herr Amy E. | Director |
Feb 14 '25 |
Option Exercise |
44.33 |
1,976 |
87,596 |
3,836 |
| Herr Amy E. | Director |
Feb 14 '25 |
Sale |
65.96 |
1,860 |
122,691 |
1,976 |
0.21%
1.22%
자본화:
|
볼륨(24시간):